{
  "docId": "019de074-704c-735b-b7a3-613838aa1bf3",
  "docSlug": "9b81d8a09c69afc3f139dc970effabde",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 39,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/25",
  "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3",
  "deckJsonHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3.json",
  "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.185,
        "w": 0.884,
        "x": 0.058,
        "y": 0.685
      },
      "kind": "list",
      "text": "Corporate: Jeff Goldberg appointed CEO in November 2022; $57.3 million in cash and available funds as of December 31, 2022; projected runway into fourth quarter of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b79a9a8-889d-4417-b10f-27efe16f0029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.185,
        "w": 0.884,
        "x": 0.058,
        "y": 0.185
      },
      "kind": "list",
      "text": "Pegtarviliase in Homocystinuria: Fast Track Designation received from FDA; Currently dosing in cohort 3 at 1.35 mg/kg once weekly in Phase 1/2 clinical trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a979a267-c36c-4c80-9d16-eb72d9118cff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.185,
        "w": 0.884,
        "x": 0.058,
        "y": 0.448
      },
      "kind": "list",
      "text": "Pegzilarginase in Arginase 1 Deficiency: MAA under review with EMA, potential decision on approval in late 2023; Continuing to engage with FDA to identify potential path to BLA resubmission",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e23e06d8-7618-466b-9cf8-47a2ea07a9bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.068,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "1 Includes cash, cash equivalents, marketable securities, and restricted cash",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4fbfdc6-cf52-4d3a-9554-e8ad66a3adb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.435,
        "x": 0.068,
        "y": 0.045
      },
      "kind": "title",
      "text": "Highlights and Upcoming Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5fda7a8-b830-4660-8b5e-2dbfb749a52e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 25,
      "beatId": "ee42496b-f81a-4970-8acd-44ab2cd043a3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact and Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document highlights the impact of Aeglea BioTherapeutics' therapies and outlines next steps for the company.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}